Stopping skin cancer -- Stat3

September 01, 2004

Cervical cancer is the second most common cancer among women worldwide. Research Human cancers generally develop through several steps -- initiation, promotion, and progression -- which require the accumulation of between 4 to 6 genetic mutations. Skin cancer is the most common cancer for both men and women. John DiGiovanni and colleagues, at The University of Texas MD Anderson Cancer Center, now show that a protein called Stat3 is required for skin cancer initiation and promotion.

Stat3 is a protein that normally acts to regulate the expression several genes in the cell. Stat3, when it is improperly activated, is known to be involved in a number of human cancers. Here researchers used a two-stage chemical skin cancer mouse model to investigate whether Stat3 is involved in one of the most common forms of cancer, and if so, at what stage.

They found that while a normal mouse, after chemical treatment, developed skin tumors, mice that were deficient in Stat3 were completely resistant to skin tumor development. The authors further showed, both in cell culture and in live animals, that they could block growth of already transformed skin cells if they inhibited Stat3 function using an oligonucleotide inhibitor. Additionally, when skin tumors were injected with this Stat3 functional inhibitor, tumor growth itself was impaired.

This study provides the first evidence that Stat3 is required for the initiation of one form of skin cancer, and that it both mediates and maintains cellular growth through expansion of these initiated cells. These data also indicate that Stat3, which has recently begun to emerge as a target for cancer therapy, may also be important for developing cancer prevention strategies.
An accompanying commentary by Jacqueline Bromberg and colleagues, of Memorial Sloan Kettering Cancer Center, provides an overview of Stat3 function in the development of cancer. It places the work by DiGiovanni and colleagues into this context and details how this study advances our understanding of and the development of treatments for cancer.

TITLE: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis

John DiGiovanni
The University of Texas M.D. Anderson Cancer Center, PO Box 389, Smithville, TX 78957, USA Phone: 512-237-9414; Fax: 512-237-2522; E-mail:

View the PDF of this article at:

ACCOMPANYING COMMENTARY: Stat3 is required for the development of skin cancer

Jacqueline Bromberg
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA Phone: 212-639-8191; Fax: 212-422-2231; E-mail:

JCI Journals

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to